Plenge 2012 Front Physiol: Difference between revisions
(Created page with "{{Publication |title=Plenge U, Belhage B, Guadalupe-Grau A, Andersen PR, Lundby C, Dela F, Stride N, Pott FC, Helge JW, Boushel R (2012) Erythropoietin treatment enhances muscle ...") ย |
No edit summary |
||
Line 1: | Line 1: | ||
{{Publication | {{Publication | ||
|title=Plenge U, Belhage B, Guadalupe-Grau A, Andersen PR, Lundby C, Dela F, Stride N, Pott FC, Helge JW, Boushel R (2012) Erythropoietin treatment enhances muscle mitochondrial capacity in humans. Front Physiol 3: 50. ย | |title=Plenge U, Belhage B, Guadalupe-Grau A, Andersen PR, Lundby C, Dela F, Stride N, Pott FC, Helge JW, Boushel R (2012) Erythropoietin treatment enhances muscle mitochondrial capacity in humans. Front Physiol 3: 50. | ||
|info=[http://www.ncbi.nlm.nih.gov/pubmed/22419911 PMID: 22419911] | |info=[http://www.ncbi.nlm.nih.gov/pubmed/22419911 PMID: 22419911] | ||
|authors=Plenge U, Belhage B, Guadalupe-Grau A, Andersen PR, Lundby C, Dela F, Stride N, Pott FC, Helge JW, Boushel R | |authors=Plenge U, Belhage B, Guadalupe-Grau A, Andersen PR, Lundby C, Dela F, Stride N, Pott FC, Helge JW, Boushel R | ||
|year=2012 | |year=2012 | ||
|journal=Front Physiol | |journal=Front Physiol | ||
|abstract=Erythropoietin (Epo) treatment has been shown to induce mitochondrial biogenesis in cardiac muscle along with enhanced mitochondrial capacity in mice. We hypothesized that recombinant human Epo (rhEpo) treatment enhances skeletal muscle mitochondrial oxidative phosphorylation (OXPHOS) capacity in humans. In six healthy volunteers rhEpo was administered by sub-cutaneous injection over | |abstract=Erythropoietin (Epo) treatment has been shown to induce mitochondrial biogenesis in cardiac muscle along with enhanced mitochondrial capacity in mice. We hypothesized that recombinant human Epo (rhEpo) treatment enhances skeletal muscle mitochondrial oxidative phosphorylation (OXPHOS) capacity in humans. In six healthy volunteers rhEpo was administered by sub-cutaneous injection over 8โ weeks with oral iron (100โ mg) supplementation taken daily. Mitochondrial OXPHOS was quantified by high-resolution respirometry in saponin-permeabilized muscle fibers obtained from biopsies of the vastus lateralis before and after rhEpo treatment. OXPHOS was determined with the mitochondrial Complex I substrates malate, glutamate, pyruvate, and Complex II substrate succinate in the presence of saturating ADP concentrations, while maximal electron transport capacity (ETS) was assessed by addition of an uncoupler. rhEpo treatment increased OXPHOS (from 92โยฑโ5 to 113โยฑโ7โpmolยทs(-1)ยทmg(-1)) and ETS (107โยฑโ4 to 143โยฑโ14โpmolยทs(-1)ยทmg(-1), pโ<โ0.05), demonstrating that Epo treatment induces an upregulation of OXPHOS and ETS in human skeletal muscle. | ||
|keywords=Erythropoietin (Epo), oral iron supplementation, maximal electron transport capacity (ETS) ย | |keywords=Erythropoietin (Epo), oral iron supplementation, maximal electron transport capacity (ETS) | ||
|mipnetlab=DK Copenhagen Boushel R | |mipnetlab=DK Copenhagen Boushel R | ||
}} | }} | ||
{{Labeling | {{Labeling | ||
|instruments=Oxygraph-2k | |instruments=Oxygraph-2k | ||
|organism=Human | |organism=Human | ||
|tissues= | |tissues=Skeletal muscle | ||
|preparations=Permeabilized | |preparations=Permeabilized tissue | ||
|enzymes=Complex I, Complex II; Succinate Dehydrogenase | |enzymes=Complex I, Complex II; Succinate Dehydrogenase | ||
|topics=Respiration; OXPHOS; ETS Capacity | |topics=Respiration; OXPHOS; ETS Capacity | ||
}} | }} |
Revision as of 02:18, 5 April 2012
Plenge U, Belhage B, Guadalupe-Grau A, Andersen PR, Lundby C, Dela F, Stride N, Pott FC, Helge JW, Boushel R (2012) Erythropoietin treatment enhances muscle mitochondrial capacity in humans. Front Physiol 3: 50. |
Plenge U, Belhage B, Guadalupe-Grau A, Andersen PR, Lundby C, Dela F, Stride N, Pott FC, Helge JW, Boushel R (2012) Front Physiol
Abstract: Erythropoietin (Epo) treatment has been shown to induce mitochondrial biogenesis in cardiac muscle along with enhanced mitochondrial capacity in mice. We hypothesized that recombinant human Epo (rhEpo) treatment enhances skeletal muscle mitochondrial oxidative phosphorylation (OXPHOS) capacity in humans. In six healthy volunteers rhEpo was administered by sub-cutaneous injection over 8โ weeks with oral iron (100โ mg) supplementation taken daily. Mitochondrial OXPHOS was quantified by high-resolution respirometry in saponin-permeabilized muscle fibers obtained from biopsies of the vastus lateralis before and after rhEpo treatment. OXPHOS was determined with the mitochondrial Complex I substrates malate, glutamate, pyruvate, and Complex II substrate succinate in the presence of saturating ADP concentrations, while maximal electron transport capacity (ETS) was assessed by addition of an uncoupler. rhEpo treatment increased OXPHOS (from 92โยฑโ5 to 113โยฑโ7โpmolยทs(-1)ยทmg(-1)) and ETS (107โยฑโ4 to 143โยฑโ14โpmolยทs(-1)ยทmg(-1), pโ<โ0.05), demonstrating that Epo treatment induces an upregulation of OXPHOS and ETS in human skeletal muscle. โข Keywords: Erythropoietin (Epo), oral iron supplementation, maximal electron transport capacity (ETS)
โข O2k-Network Lab: DK Copenhagen Boushel R
Labels:
Organism: Human
Tissue;cell: Skeletal muscle
Preparation: Permeabilized tissue
Enzyme: Complex I, Complex II; Succinate Dehydrogenase"Complex II; Succinate Dehydrogenase" is not in the list (Adenine nucleotide translocase, Complex I, Complex II;succinate dehydrogenase, Complex III, Complex IV;cytochrome c oxidase, Complex V;ATP synthase, Inner mt-membrane transporter, Marker enzyme, Supercomplex, TCA cycle and matrix dehydrogenases, ...) of allowed values for the "Enzyme" property.
Regulation: Respiration; OXPHOS; ETS Capacity"Respiration; OXPHOS; ETS Capacity" is not in the list (Aerobic glycolysis, ADP, ATP, ATP production, AMP, Calcium, Coupling efficiency;uncoupling, Cyt c, Flux control, Inhibitor, ...) of allowed values for the "Respiration and regulation" property.
HRR: Oxygraph-2k